Dr. Reddy`s Laboratories Ltd

Research Dr. Reddy`s Laboratories Ltd (RDY) on Bullrun: market cap USD 10.15B, P/E 27.4, dividend yield 0.7%. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is USD 10.15B; P/E is 27.4; dividend yield is 0.7%.

Peer valuation comparison

Latest P/E is 27.37x versus a Healthcare sector median of 24.34x (12.5% above).

Latest dividend yield is 0.68% versus a Healthcare sector median of 2.12% (67.9% below).

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025INR 345.83BINR 56.59BINR 24.26B55.2%67.89INR 18.66BINR 67.73BINR 372.37B
FY2024INR 311.31BINR 53.68BINR 6.52B59.3%64.39INR 12.29BINR 51.09BINR 317.72B

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-28USD 10.15B27.40.7%0.08
20252025-12-31USD 11.69B18.00.6%0.09
20242024-12-31USD 13.15B20.50.6%0.1
20232023-12-29USD 11.59B18.81.4%0.2
20222022-12-30USD 8.59B21.64.5%0.47
20212021-12-31USD 10.88B30.40.5%0.07

Dividend history

Latest trailing dividend snapshot: annual dividend/share 0.08 USD, yield 0.7%.

About Dr. Reddy`s Laboratories Ltd

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment.

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Dr. Reddy`s Laboratories Ltd's market cap?

Dr. Reddy`s Laboratories Ltd's market capitalization is USD 10.15B.

What is Dr. Reddy`s Laboratories Ltd's P/E ratio?

Dr. Reddy`s Laboratories Ltd's price-to-earnings (P/E) ratio is 27.4.

Does Dr. Reddy`s Laboratories Ltd pay a dividend?

Dr. Reddy`s Laboratories Ltd has a dividend yield of 0.7%.

What does Dr. Reddy`s Laboratories Ltd do?

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. Its Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.